Financial Forecast - The company forecasts a net profit attributable to shareholders of between 14.4463 million and 21.6694 million yuan for 2024, representing a decline of 42.40% to 61.60% compared to the previous year's profit of 37.6192 million yuan[3] - The net profit after deducting non-recurring gains and losses is expected to be between 4.5512 million and 6.8268 million yuan, a decrease of 76.23% to 84.16% from the previous year's profit of 28.7262 million yuan[3] Performance Decline Factors - The decline in performance is attributed to fluctuations in industry demand, intense price competition, and lower-than-expected order intake impacting overall performance[5] - The company is experiencing increased costs due to the construction of its preclinical new drug R&D base projects, which are still in the ramp-up phase[6] R&D Investment - R&D expenses have increased year-on-year as the company continues to invest in research and technology platforms[6] Non-Recurring Gains and Losses - Non-recurring gains and losses are estimated to impact net profit by approximately 12 million yuan, mainly from government subsidies and investment income[6] Performance Forecast Disclaimer - The company emphasizes that the performance forecast is based on preliminary estimates and the final financial data will be disclosed in the 2024 annual report[7]
泓博医药(301230) - 2024 Q4 - 年度业绩预告